KAAACI Allergic Rhinitis Guidelines: Part 1. Update in pharmacotherapy
10.4168/aard.2023.11.3.117
- Author:
Minji KIM
1
;
Sung-Yoon KANG
;
Song-I YANG
;
Il Hwan LEE
;
Gwanghui RYU
;
Mi-Ae KIM
;
Sang Min LEE
;
Hyun-Jung KIM
;
Do-Yang PARK
;
Yong Ju LEE
;
Dong-Kyu KIM
;
Do Hyun KIM
;
Young Joon JUN
;
Sang Chul PARK
;
Bong-Seong KIM
;
Soojie CHUNG
;
Hyun Jong LEE
;
Hyo-Bin KIM
;
Jeong-Hee CHOI
;
Gil-Soon CHOI
;
Hyeon-Jong YANG
;
Soo Whan KIM
Author Information
1. Department of Pediatrics, Chungnam National University Sejong Hospital, Sejong, Korea
- Publication Type:REVIEW
- From:Allergy, Asthma & Respiratory Disease
2023;11(3):117-125
- CountryRepublic of Korea
- Language:English
-
Abstract:
The prevalence of allergic rhinitis (AR) and the socioeconomic burden associated with the medical cost and quality of life of AR have progressively increased. Therefore, practical guidelines for the appropriate management of AR need to be developed based on scientific evidence considering the real-world environment, values, and preferences of patients and physicians. The Korean Academy of Asthma, Allergy and Clinical Immunology revised clinical guidelines for AR to address key clinical questions of the management of AR. Part 1 of the revised guideline covers the pharmacological management of patients with AR in Korea. Through a meta-analysis and a systematic review, we made 4 recommendations for AR pharmacotherapy, including intranasal corticosteroid (INCS)/intranasal antihistamine combination therapy, oral antihistamine/INCS combination therapy, leukotriene receptor antagonist treatment in AR patients with asthma, and prophylactic treatment for patients with pollen-induced AR. However, all recommendations are conditional because of the low or very low evidence of certainty. Well-designed and strictly executed randomized controlled trials are needed to measure and report appropriate outcomes.
